Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy
in the Induction Therapy for Ph-Negative Acute Lymphoblastic
Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell
Trial

a 2022

Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial

SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK et. al.

Základní údaje

Originální název

Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial

Autoři

SALEK, Cyril, František FOLBER (203 Česká republika, domácí), Štěpán HRABOVSKÝ (203 Česká republika, domácí), Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA a Michael DOUBEK

Vydání

2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

BLINA-CELL

Kód RIV

RIV/00216224:14110/22:00133021

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1182/blood-2022-157361

UT WoS

000893223203131

Klíčová slova česky

blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia

Klíčová slova anglicky

blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia

Štítky

Excelence Science, MU, RIV, user, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 4. 2024 14:55, Mgr. Tereza Miškechová

Anotace

V originále

Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA a Michael DOUBEK. Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial. 2022. Dostupné z: https://dx.doi.org/10.1182/blood-2022-157361.

@proceedings{2361066,
   author = {Salek, Cyril and Folber, František and Hrabovský, Štěpán and Koristek, Zdenek and Horacek, Jan M and Fronkova, Eva and Soukup, Petr and Benkova, Katerina and Cetkovsky, Petr and Trka, Jan and Doubek, Michael},
   doi = {http://dx.doi.org/10.1182/blood-2022-157361},
   keywords = {blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia},
   language = {eng},
   title = {Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial},
   url = {https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose},
   year = {2022}
}

TY  - CONF
ID  - 2361066
AU  - Salek, Cyril - Folber, František - Hrabovský, Štěpán - Koristek, Zdenek - Horacek, Jan M - Fronkova, Eva - Soukup, Petr - Benkova, Katerina - Cetkovsky, Petr - Trka, Jan - Doubek, Michael
PY  - 2022
TI  - Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
KW  - blinatumomab
KW  - high-dose chemotherapy
KW  - acute lymphoblastic leukemia
UR  - https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose
N2  - Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.
ER  -

SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA a Michael DOUBEK. \textit{Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial}. 2022. Dostupné z: https://dx.doi.org/10.1182/blood-2022-157361.

Podrobný výpis o publikaci